Titlebook: Direct Oral Anticoagulants; From Pharmacology to Riccardo Proietti,Ahmed AlTurki,T. Jared Bunch Book 2021 Springer Nature Switzerland AG 20

只看該作者 · 發(fā)表于 2025-3-21 16:05:32

書(shū)目名稱Direct Oral Anticoagulants影響因子(影響力)

書(shū)目名稱Direct Oral Anticoagulants影響因子(影響力)學(xué)科排名

書(shū)目名稱Direct Oral Anticoagulants網(wǎng)絡(luò)公開(kāi)度

書(shū)目名稱Direct Oral Anticoagulants網(wǎng)絡(luò)公開(kāi)度學(xué)科排名

書(shū)目名稱Direct Oral Anticoagulants被引頻次

書(shū)目名稱Direct Oral Anticoagulants被引頻次學(xué)科排名

書(shū)目名稱Direct Oral Anticoagulants年度引用

書(shū)目名稱Direct Oral Anticoagulants年度引用學(xué)科排名

書(shū)目名稱Direct Oral Anticoagulants讀者反饋

書(shū)目名稱Direct Oral Anticoagulants讀者反饋學(xué)科排名

只看該作者 · 發(fā)表于 2025-3-21 21:12:49

只看該作者 · 發(fā)表于 2025-3-22 01:43:31

Pharmacokinetics and Pharmacodynamics of DOAC, dabigatran (a reversible direct thrombin inhibitor) and the direct factor Xa inhibitors rivaroxaban, apixaban, and edoxaban offer fixed dosing, more predictable pharmacokinetics and fewer interactions with drugs and food than warfarin. Results from clinical trials demonstrated an improved benefit-r

只看該作者 · 發(fā)表于 2025-3-22 05:32:17

只看該作者 · 發(fā)表于 2025-3-22 10:47:33

只看該作者 · 發(fā)表于 2025-3-22 13:59:12

Risk Stratification For and Use of DOAC Therapies for Stroke Prevention in Patient with Atrial Fibrant agents play a key role in preventing this complication. Through years, several risk stratification algorithms have been investigated, while others are still object of debate. According to current guidelines, CHA2DS2VASc score and HAS-BLED score are the ones suggested for stroke and bleeding risk

只看該作者 · 發(fā)表于 2025-3-22 20:39:30

Use of DOAC in Patients with Kidney Disease,morrhagic events are increased in patients with kidney disease. Oral anticoagulation therapy, nowadays preferably with direct oral anticoagulants (DOACs), represents the cornerstone for ischemic stroke prevention in high-risk patients. However, all four available DOACs (dabigatran, apixaban, rivarox

只看該作者 · 發(fā)表于 2025-3-23 00:26:33

只看該作者 · 發(fā)表于 2025-3-23 03:09:14

,The “Obesity Paradox” and the Use of NOAC,ovascular (CV) risk, more and more evidences suggest a favorable prognosis in obese subjects with cardiovascular disease (CVD), a phenomenon known as “obesity paradox.” Obesity paradox has been demonstrated in various CVD including atrial fibrillation (AF) and venous thromboembolism (VTE) for which

只看該作者 · 發(fā)表于 2025-3-23 05:41:57

		自動(dòng)登錄	找回密碼
密碼			To register

關(guān)于派博傳思			派博傳思旗下網(wǎng)站			友情鏈接
派博傳思介紹	公司地理位置	論文服務(wù)流程	影響因子官網(wǎng)	吾愛(ài)論文網(wǎng)	大講堂	北京大學(xué)	Oxford Uni.	Harvard Uni.
發(fā)展歷史沿革	期刊點(diǎn)評(píng)	投稿經(jīng)驗(yàn)總結(jié)	SCIENCEGARD	IMPACTFACTOR	派博系數(shù)	清華大學(xué)	Yale Uni.	Stanford Uni.
\|Archiver\|手機(jī)版\|小黑屋\| 派博傳思國(guó)際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-10 11:10
Copyright © 2001-2015 派博傳思京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved